Preparing for NASH and Other New Liver Treatments

1:30 PM - 2:25 PM (EST), Monday, February 10, 2020 ・ Lyceum Complex
Approximately 5% of people in the U.S. are at risk for NASH and it is on track to be the dominant disease causing liver failure—but no therapeutic medicines have yet been approved. More than 50 companies are positioning for a stake of providing treatments to patients in an expected $35B market by 2025. With high profile target failures in bile acid receptors and caspases, companies are finding opportunities in combination therapies, new targets, and diversifying the risks by testing potential targets with other liver diseases. Hear from a panel of industry insiders on the competitive landscape for NASH and how progress and setbacks there are affecting liver treatment development broadly.
Moderator
photo
Managing Director & Senior Research Analyst, Co-Head of Biotechnology Research
ROTH Capital Partners
Speakers
photo
Senior Vice President and Chief Scientific Officer, Internal Medicine Research Unit
Pfizer Inc.
photo
Founder and CEO
RGA Consulting
photo
Chief Executive Officer
GENFIT
photo
President and CEO
Intercept Pharmaceuticals
photo
Chief Executive Officer and Acting Chief Financial Officer
NGM Bio